FreeStyle Libre 3 vs Dexcom G7: Side-by-Side Accuracy, Wear Time, and Hypoglycemia Detection
In the first head-to-head study to put them on the same arms at the same time, the FreeStyle Libre 3 logged a mean absolute relative difference (MARD) of 8.9% and the Dexcom G7 logged 13.6%, a gap that surprised researchers because the two devices look nearly identical on paper. A year later, two newer head-to-head studies found them essentially tied. So which one is actually more accurate, and does it matter for the way you'd use it?
Both are dime-sized continuous glucose monitors that ship ready to wear and transmit to a phone or smartwatch in real time. The differences are real but smaller than the marketing makes them sound. Below is the side-by-side data, then a section on where each one tends to win.
The Side-by-Side
| Feature | FreeStyle Libre 3 | Dexcom G7 |
|---|---|---|
| Pivotal trial MARD | 7.8% (n=100) | 8.2% (arm placement, n=316) |
| Head-to-head MARD (multicenter, n=55) | 8.9% | 13.6% |
| Head-to-head MARD (lab, n=24, 15 days) | 11.6% (vs YSI) | 12.0% (vs YSI) |
| Sensor wear time | 14 days | 10.5 days |
| Predictive low alert | No | Yes (Urgent Low Soon) |
The pivotal trials, run separately, both reported single-digit MARD: 7.8% for the FreeStyle Libre 3 across 100 participants and 6,845 sensor-comparator pairs, and 8.2% for the Dexcom G7 across 316 participants and 77,774 matched pairs. These results put both devices in the same accuracy tier.
How Accurate Is Each One in Real Life
The disagreement between the two CGMs gets interesting once they're worn at the same time on the same person. The first multicenter study to compare them this way, published in 2024, enrolled 55 adults with type 1 or type 2 diabetes and recorded sensor readings against laboratory-grade Yellow Springs Instrument values.
The FreeStyle Libre 3 came in at 8.9% MARD; the Dexcom G7 at 13.6%. That gap held across glucose ranges and across days of wear, and the difference was statistically significant.
The picture gets murkier when more recent studies enter the mix. In a 2025 lab study of 24 adults with type 1 diabetes who wore the Libre 3, Dexcom G7, and Medtronic Simplera in parallel for 15 days, MARDs against the YSI reference were 11.6%, 12.0%, and 11.6% respectively, with no meaningful gap between the Libre 3 and G7. And in a 2025 prospective study of 20 adults with type 1 diabetes wearing all three CGMs across an active weekend camp, median absolute relative differences were 7.5% for Libre 3 and 8.4% for G7, again statistically indistinguishable.
The plausible explanation: study design and patient mix swing MARD by several percentage points. Pivotal trials use tightly controlled in-clinic visits with frequent glycemic excursions; real-world studies include exercise, meals, and longer wear periods. Across these settings, the two devices tend to land in the same neighborhood, and the 2024 point-accuracy gap may have reflected a particular study cohort more than a stable, generalizable difference.
What's consistent across studies: neither device is perfect, and accuracy declines under fast-changing glucose. The 14-day wear pattern matters here too. The Libre 3's pivotal trial reported stable performance across the full 14 days, while the G7's pivotal trial covered 10.5 days; over a typical month, the Libre 3 swaps out fewer times.
Where They Part Ways
Equal-on-average doesn't mean equivalent in every situation. A few scenarios separate them.
A 2024 study assessed both sensors during repetitive recreational scuba diving in 13 adults with type 1 diabetes across 202 dives. The Dexcom G7's MARD climbed to 31%; the Libre 3's was 14.2%.
Surveillance error grid analysis put 97.4% of the Libre 3's readings in the no-risk zone vs 82.1% for the G7. Neither sensor was accurate enough for non-adjunctive use in that setting, and the researchers recommended capillary checks before each dive. If you're an athlete who spends time underwater or under high mechanical stress, the Libre 3 tolerated those conditions better.
The Dexcom G7 carries a predictive Urgent Low Soon alert that fires before glucose actually drops below the threshold. The Libre 3 has threshold-based alarms but no predictive low alert.
In a 12-week study of 29 adults with type 1 diabetes who switched from the FreeStyle Libre 2 to the Dexcom G7, time spent below 70 mg/dL dropped from a median of 3.0% to 2.0%, and glucose coefficient of variation fell from 39.3% to 37.2%. If you've had nocturnal lows or hypoglycemia unawareness, that predictive feature is the single biggest functional difference between these two devices.
When the question is detecting a low that's already happening, the scuba study found the Libre 3 better at identifying hypoglycemia, with a diagnostic odds ratio of 254 vs 59 for the G7.
The two devices may also disagree on the same glucose level. A separate 14-day study of 23 participants wearing both sensors in parallel showed substantially different glycemic metrics between systems, with intraparticipant discrepancies large enough to change a clinician's therapy recommendation.
A 2025 secret-shopper study of 125 community pharmacies in Austin compared pharmacist counseling on each device. Pharmacists provided counseling for the FreeStyle Libre 3 in 88.6% of visits vs 71.1% for the Dexcom G7. Pharmacists demonstrated application technique correctly 78.9% of the time for the Libre 3 vs 56.3% for the G7.
If you're newly starting CGM and counting on your pharmacist for guidance, the Libre 3 is more likely to get a competent walkthrough at the counter.
The Clinical Benefit Is Bigger Than the Difference Between Them
Step back and the bigger picture is that any modern CGM beats fingersticks by a wide margin, and the choice between Libre 3 and G7 matters less than the choice to wear one at all.
The DIAMOND trial in 158 adults with type 1 diabetes on multiple daily injections found that 24 weeks of CGM lowered HbA1c by 0.6% vs usual care. The MOBILE trial in 175 adults with type 2 diabetes on basal insulin found CGM raised time in the 70 to 180 mg/dL range from 43% to 59% and dropped time above 250 mg/dL from 27% to 11%.
A real-world cohort of 41,753 insulin-treated patients showed a 0.4% HbA1c drop and significantly fewer emergency visits for hypoglycemia after starting real-time CGM. And in a 2025 propensity-matched analysis of 9,258 adults with type 2 diabetes, the highest-frequency users (more than 75% sensor wear) saw HbA1c drop by 1.52 percentage points at 12 months vs 0.63 in non-users.
Across these trials, the benefit doesn't hinge on which CGM brand you wore. It hinges on whether you wore one and how often.
Which CGM Is Right for You
The honest answer is that the two devices are close enough that secondary factors should drive the call.
- Pick the FreeStyle Libre 3 if you want longer wear time (14 vs 10 days), easier pharmacy support at setup, and better accuracy under physical stress.
- Pick the Dexcom G7 if you want a predictive low alert that fires before glucose drops or the option to wear the sensor on the abdomen rather than the arm.
- Either is a strong choice if you're trading fingersticks for continuous data and want the metabolic insight that comes with seeing every meal, run, and night of sleep mapped to glucose.
If you're ready to start, Instalab's FreeStyle Libre 3 program ($99) includes the sensor and physician oversight to get you set up and answer questions during the first few months.
Choosing Between Libre 3 and G7
The published pivotal trials put both devices in single-digit MARD territory, and most recent head-to-head studies show them tied within a percentage point or two. Where they diverge, the Libre 3 has the edge in wear time and accuracy under physical stress; the G7 has the edge in predictive hypoglycemia alerts and placement flexibility. Either one delivers the clinical benefit that matters most, which is replacing self-monitoring with continuous data that you'll actually look at multiple times a day.
Prescribed by a licensed physician. Sent to your pharmacy.